van Kempen: #ampeurope2018 Expects 2020-2025: list of molecular guidelines '18 JTO https://t.co/VOJRyb6h40
8:16am May 1st 2018 via Twitter Web Client
van Kempen: #ampeurope2018 '80's 3 types; 2002-2013 'big bang': BRAF in melanoma, then in NSCLC. Fig from https://t.co/LcWhOYVf5G
8:13am May 1st 2018 via Twitter Web Client
van Kempen: #ampeurope2018 1914 lung ca started to increase as smoking became more prevalent. 1970's: HSCLC, SCLC; w/chemoRx
8:11am May 1st 2018 via Twitter Web Client
Leon van Kempen (Groningen NE) #ampeurope2018 RNA profiling of gene fusion events in lung cancer using NanoString nCounter Platform
Gerlach: #ampeurope2018 'We have a great booth'; FYI take a look at their virtual reality demo! FWIW https://t.co/dIfeOVO0jR from #AACR18
8:10am May 1st 2018 via Twitter Web Client
Gerlach: #ampeurope2018mRNA, lncRNA, gene fusions, miRNA, SNV, CNV, protein: 3D biology. Now: morphology-driven digital spatial profiling
8:09am May 1st 2018 via Twitter Web Client
Gerlach: Up to 800 reporter probes, two probes of 50bp apiece #ampeurope2018 biotinylated probe captured on slide, no ampl
8:08am May 1st 2018 via Twitter Web Client
Gerlach: #ampeurope2018 "Simple enough for Dx." (Yet disclaimed right underneath 'For Research use only, not for us… https://t.co/xCOJIWEsmQ
8:07am May 1st 2018 via Twitter Web Client
Gerlach: #ampeurope2018 Software (nSolver analysis), even data analysis as a service, and contract mfg.
8:06am May 1st 2018 via Twitter Web Client
Gerlach: #ampeurope2018 'enabling the fastest path to signature developmnt; panels for RNA, DNA, Protein. FDA-marked ProSigna assay
8:05am May 1st 2018 via Twitter Web Client
Nanostring workshop: Jay Gerlach, Dir Product Mgmt #ampeurope2018
8:04am May 1st 2018 via Twitter Web Client
VanderWalde: #ampeurope2018 In CRC: 95% of MSI-H also TMB-H; 82% of TMB-H also MSI-H.
6:19am May 1st 2018 via Twitter Web Client
VanderWalde: #ampeurope2018 70% of MSI-H also TMB-H; 27% of TMB-H also MSI-H
6:18am May 1st 2018 via Twitter Web Client
VanderWalde: #ampeurope2018 Shows overall (busy) Venn: MSI-H, SMB-H, both, total PD-L1+, and none. Small overlap, MSI/TMB higher
VanderWalde: #ampeurope2018 Shows dot plot from ref, MSI status by NGS cp to Fragment Analysis (FA).
6:17am May 1st 2018 via Twitter Web Client
VanderWalde: #ampeurope2018 His recent publ https://t.co/ZnFSpKibwa MSI on a large number of pts. 2189 pts comparsi… https://t.co/ugWNPbH6iF
6:14am May 1st 2018 via Twitter Web Client
VanderWalde: #ampeurope2018 As a surgical oncologist: just wants to 'know what to do'. Freq of MSI-H: shows same Le '17 fig
6:07am May 1st 2018 via Twitter Web Client
VanderWalde: #ampeurope2018 Need a large panel (>1.5MB); at 500x can detect VAF at 5%. But is it relevant to TMB? F… https://t.co/BOBLeHD
6:00am May 1st 2018 via Twitter Web Client
VanderWalde: #ampeurope2018 As a medical oncologist: muts/MB, acquired not germline. Accuml. over time, '13 Lawrence https://t.co/b8tS2QX0fj
5:58am May 1st 2018 via Twitter Web Client
VanderWalde: #ampeurope2018 But cutoff seemed to be a bit of hand-waving; ajuv+ Nivo response corr w/TMB '18 NEJM https://t.co/unOxrlmQEv
5:56am May 1st 2018 via Twitter Web Client
VanderWalde: #ampeurope2018 PD-L1 is impt; however there are different tests. Bladder ca: https://t.co/uGlQID3A6g S… https://t.co/3xlBqVhAn2
5:54am May 1st 2018 via Twitter Web Client
VanderWalde: #ampeurope2018 '18 NEJM https://t.co/SPxi9K6Bsf Pembro + chemo in metastatic NSCLC OS for chemo + PD-1… https://t.co/WVq5hex7X2
5:52am May 1st 2018 via Twitter Web Client
Ari VanderWalde (TN USA): #ampeurope2018 Microsatellite Instability in Relation to PDL1 Expression and Tumor Mutati… https://t.co/l6nxiph64D
5:49am May 1st 2018 via Twitter Web Client
Q: A centralized approache to TMB? Stenzinger: #ampeurope2018 In DE, 15K to 20K pts to screen, TMB is so complex, n… https://t.co/feu8dOTXQl
5:16am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 'Real life clinical utility of TMB: CURRENTLY UNKNOWN' (his quote). Critical pt: bioinformatics. C to T from FFPE
5:11am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 'WES sounds robust but it is not'. A platform-dependent measurement, poster used FOne data.
5:10am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 "0.5MB will not work; think of 1MB or above for TMB" #AACR18 poster 5528 https://t.co/FhAG3M2iep
5:09am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 Also CRC, simulated TCGA data, 1.4MB panel, panel cutoff 10/MB. 'Size and composition of panels matter'
5:08am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 Clonality, sub-clonality: include a 10% VAF? Shows unpubl data w/cutoff of only 3 mut/MB… https://t.co/VrcIzu9zuE
Stenzinger: #ampeurope2018 Also size, composition of panels, effect of germline events. Not via subtracting blood, not standardized
5:04am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 So many variables: prenanalytical tumor cellularity, DNA quality; sequence enrichment panel (need >>0.5MB)
5:03am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 BMS quotes from Sci Am Feb 18 https://t.co/WtaRueyqTI 'no std way to measure or report TMB'
5:02am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 Det TMB cutoff? CheckMate 568 shows ROC curves, TMB at 9-10 muts/MB w/AUC 0.73
4:58am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 Hi mut load group PD-L1 nice response. #AACR18 Checkmate 227: NSCLC https://t.co/NtAeEy4jKb
4:57am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 Showing utility in clin trial: CheckMate 26 prosp. chemo vs Nivo failed completely. Retrospective, learned
4:55am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 Plot of TMB vs ORR, where Merkel-cell is outlier, and CRC MMR-def another one. 'But be c… https://t.co/9Us9KJ44zn
4:54am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 Showing data from Rizvi '15, '14 CTLA-4 https://t.co/8RGyIWR0GC TMB and resp rates https://t.co/dhqMA0ts8n
Stenzinger: #ampeurope2018 DNA repair def beyond MSI: fig from https://t.co/TdqJaJ5lox Several hundred genes involved with DNA repair.
4:50am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 EGFR del 19: you still want to know if its a lung adenocarcinoma. For MSI-H, you don't care, Pembro Rx
4:49am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 Points to FDA approval for MSI-H, first histology-agnostic biomarker. US FDA 'a game-changer'.
Stenzinger: #ampeurope2018 The MSI-H predicts response to PD-1 across major cancer types, endometrial at the top. B… https://t.co/OVjMSY3DYJ
4:48am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 Targeting PD-1 in MSI-driven tumors, sporadic accumulating TMB later in life '15 https://t.co/aWXuwqo4hy
4:47am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 And Rizvi '15 https://t.co/2HHXLoc6zK Drivign mutational load w/PD-1 in NSCLC
4:46am May 1st 2018 via Twitter Web Client
Stenzinger: #ampeurope2018 Connecting TMB to neoantigens is not 'that new'. Vogelstein's '13 paper, https://t.co/VJtwNJoaSD
Stenzinger: #ampeurope2018 Reviews genetic heterogeneity, why do some pts take different paths down the 'mountain topology' landscape?
4:44am May 1st 2018 via Twitter Web Client
Albrecht Stenzinger: #ampeurope2018 The evolution of Tumour mutational Burden (TMB) into clinical research
4:43am May 1st 2018 via Twitter Web Client
Q: Anything unusual about 2 samples failed? Heydt: #ampeurope2018 One was control, another high quality DNA, just sample handling.
4:39am May 1st 2018 via Twitter Web Client
Heydt: #ampeurope2018 Local data analysis version needed 'esp in DE'. TST170 too small for TMB. Need for total workflow validation.
4:38am May 1st 2018 via Twitter Web Client
Heydt: #ampeurope2018 Concl: works 'well with even very low DNA, RNA conc in cp with other methods'. Usable but - a… https://t.co/Pq4lWljj0q
4:37am May 1st 2018 via Twitter Web Client
Heydt: #ampeurope2018 ROS1 xloc, positive by FISH, IHC, Archer, Agilent, Nanostring. Also seen in TST.
4:36am May 1st 2018 via Twitter Web Client
